FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281716762> ?p ?o ?g. }

• W4281716762 endingPage "e21008" @default.
• W4281716762 startingPage "e21008" @default.
• W4281716762 abstract "e21008 Background: Anaplastic lymphoma kinase (ALK) is one of the major oncogenic driver genes in lung cancer, and fusion as the main mutation type, of which EML4 is the most common fusion ligand. With the development of next-generation sequencing (NGS), some other rare fusion ligands and complex fusions have been discovered. The prognosis of patients with EML4-ALK fusion, non EML4-ALK fusion and multiple ALK fusion was different. Methods: We retrospectively analyzed NGS (including tissue, blood, or other body fluid samples) in 61 patients with ALK[+] lung cancer, including 59 patients with NSCLC and 2 patients with SCLC. Grouping was determined according to whether it was EML4-ALK fusion and multiple fusion. Results: In our data, the partner fused to the ALK gene are diverse, including EML4, KIF5B, TSN and others. Among them, EML4 was the most common ligand in ALK[+] NSCLC, accounting for 93.2% (55/59). Among the different fusion sites of EML4-ALK, V1 (E13:A20) and V3 (E6:A20) mutations were the most common, accounting for 45.5% (25/55) and 41.8% (23/55), respectively. Several novel ALK fusion partners were discovered in this study, including MCFD2, LINC01251, MVP17, CREG2, LINCO1498 and so on. In addition, the incidence of intergenic sequence-ALK fusions was 16.4% (10/61), such as ANXA4-ALK(A[intergenic]:A20), CREG2-ALK (C[intergenic]:A20), HCN1-ALK(H[intergenic]:A20), TSN-ALK(T[intergenic]:A20), RSAD2-ALK(R [intergenic]:A20) and so on. 19.0% (12/61) of the patient had multiple fusion, of which only one patient had multiple fusion of EML4-ALK (V2+V5'+V3a/b), and the remaining patients had co-fusion of EML4-ALK and non EML4-ALK (Table). V3 were more likely to coexist with non EML4-ALK fusions than V1 or other variants (P = 0.047). Multiple fusions were more likely to occur with non EML4-ALK fusions (P < 0.000). Compared with EML4-ALK fusion, mPFS treated with crizotinib in non EML4-ALK fusion were significantly shorter (18.2 vs. 8.5 months, P = 0.035). In the context of crizotinib treatment, multiple fusions were associated with worse mPFS compared with single fusions (13.8 vs. 8.4 months, P = 0.008). In addition, For SCLC patients with ALK fusion (n = 2), the PFS of crizotinib treatment were 8.0 and 30.6 months, respectively. Conclusions: Due to the heterogeneity of tumor development resulting in the diversity of ALK fusions, non EML4-ALK fusions and multiple fusions imply a poorer response to crizotinib. ALK gene status prior to ALK-TKI therapy helps predict drug efficacy and patient prognosis.[Table: see text]" @default.
• W4281716762 created "2022-06-13" @default.
• W4281716762 creator A5016254929 @default.
• W4281716762 creator A5022950764 @default.
• W4281716762 creator A5023643410 @default.
• W4281716762 creator A5027202789 @default.
• W4281716762 creator A5030251159 @default.
• W4281716762 creator A5038851564 @default.
• W4281716762 creator A5047947521 @default.
• W4281716762 creator A5049794273 @default.
• W4281716762 creator A5060535671 @default.
• W4281716762 creator A5061316406 @default.
• W4281716762 creator A5079974007 @default.
• W4281716762 creator A5080932283 @default.
• W4281716762 creator A5087843295 @default.
• W4281716762 date "2022-06-01" @default.
• W4281716762 modified "2023-09-26" @default.
• W4281716762 title "ALK fusion typing and response to crizotinib in ALK+ lung cancer-naive patients." @default.
• W4281716762 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e21008" @default.
• W4281716762 hasPublicationYear "2022" @default.
• W4281716762 type Work @default.
• W4281716762 citedByCount "0" @default.
• W4281716762 crossrefType "journal-article" @default.
• W4281716762 hasAuthorship W4281716762A5016254929 @default.
• W4281716762 hasAuthorship W4281716762A5022950764 @default.
• W4281716762 hasAuthorship W4281716762A5023643410 @default.
• W4281716762 hasAuthorship W4281716762A5027202789 @default.
• W4281716762 hasAuthorship W4281716762A5030251159 @default.
• W4281716762 hasAuthorship W4281716762A5038851564 @default.
• W4281716762 hasAuthorship W4281716762A5047947521 @default.
• W4281716762 hasAuthorship W4281716762A5049794273 @default.
• W4281716762 hasAuthorship W4281716762A5060535671 @default.
• W4281716762 hasAuthorship W4281716762A5061316406 @default.
• W4281716762 hasAuthorship W4281716762A5079974007 @default.
• W4281716762 hasAuthorship W4281716762A5080932283 @default.
• W4281716762 hasAuthorship W4281716762A5087843295 @default.
• W4281716762 hasConcept C104317684 @default.
• W4281716762 hasConcept C111829193 @default.
• W4281716762 hasConcept C117643217 @default.
• W4281716762 hasConcept C143998085 @default.
• W4281716762 hasConcept C2776232967 @default.
• W4281716762 hasConcept C2776256026 @default.
• W4281716762 hasConcept C2779422266 @default.
• W4281716762 hasConcept C502942594 @default.
• W4281716762 hasConcept C54355233 @default.
• W4281716762 hasConcept C71924100 @default.
• W4281716762 hasConcept C86803240 @default.
• W4281716762 hasConceptScore W4281716762C104317684 @default.
• W4281716762 hasConceptScore W4281716762C111829193 @default.
• W4281716762 hasConceptScore W4281716762C117643217 @default.
• W4281716762 hasConceptScore W4281716762C143998085 @default.
• W4281716762 hasConceptScore W4281716762C2776232967 @default.
• W4281716762 hasConceptScore W4281716762C2776256026 @default.
• W4281716762 hasConceptScore W4281716762C2779422266 @default.
• W4281716762 hasConceptScore W4281716762C502942594 @default.
• W4281716762 hasConceptScore W4281716762C54355233 @default.
• W4281716762 hasConceptScore W4281716762C71924100 @default.
• W4281716762 hasConceptScore W4281716762C86803240 @default.
• W4281716762 hasIssue "16_suppl" @default.
• W4281716762 hasLocation W42817167621 @default.
• W4281716762 hasOpenAccess W4281716762 @default.
• W4281716762 hasPrimaryLocation W42817167621 @default.
• W4281716762 hasRelatedWork W2108851944 @default.
• W4281716762 hasRelatedWork W2134701411 @default.
• W4281716762 hasRelatedWork W2325577077 @default.
• W4281716762 hasRelatedWork W2586889471 @default.
• W4281716762 hasRelatedWork W2782740441 @default.
• W4281716762 hasRelatedWork W2797353951 @default.
• W4281716762 hasRelatedWork W2955381639 @default.
• W4281716762 hasRelatedWork W3029882742 @default.
• W4281716762 hasRelatedWork W4242453578 @default.
• W4281716762 hasRelatedWork W4280647591 @default.
• W4281716762 hasVolume "40" @default.
• W4281716762 isParatext "false" @default.
• W4281716762 isRetracted "false" @default.
• W4281716762 workType "article" @default.